Abiomed (ABMD) Tops Q3 EPS by 26c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Northland Capital Markets Upgrades ABIOMED (ABMD) to Market Perform
January 28, 2015 7:23 AM ESTNorthland Capital Markets upgraded ABIOMED (NASDAQ: ABMD) from Underperform to Market Perform with a price target of $40.00 (from $14.00).
Analyst Suraj Kalia comments, "We confess we have been dead wrong on this stock since the failure of the PROTECT-II pivotal trial. As... More
